HPEL (Hyperlipidemia) Predicted ASCVD Increment Calculator

Current LDL-C (mg/dL) Reference/Target LDL-C (mg/dL) (e.g., 70) HPEL (Hyperlipidemia) Predicted ASCVD Increment: Explanation and Clinical Context This tool estimates the incremental atherosclerotic cardiovascular disease (ASCVD) risk attributable to elevated LDL-C relative to a user-defined reference (commonly 70 mg/dL) by applying a log-linear relationship between LDL-C and major vascular events derived from large, individual-patient meta-analyses. Users first enter a baseline 10-year ASCVD risk (e.g., from the ACC/AHA Pooled Cohort Equations) and then input the current and reference LDL-C. The calculator applies a multiplicative risk multiplier based on the well-established finding that each 1.0 mmol/L (≈38.7 mg/dL) reduction in LDL-C is associated with about a 21–22% relative reduction in major vascular events (rate ratio ≈0.79).

Accordingly, an LDL-C elevation above the reference produces a proportional increase in predicted risk. The output includes the adjusted 10-year risk, the absolute (%-point) increase, and the relative (%) increase versus baseline. Clinical Significance The approach reflects the causal, continuous, and log-linear exposure–response between LDL-C and ASCVD.

It complements (not replaces) global risk estimators by making the LDL-attributable component explicit, useful for shared decision-making about lipid-lowering therapy intensity and targets. Because the underlying evidence shows consistent proportional benefit across risk strata, the same multiplier can be applied to a wide range of baseline risks. However, estimates are approximations: they assume average treatment effects and do not account for competing risks, polygenic risk, or additional lipoproteins (e.g., Lp(a), ApoB, sdLDL), which can further modify risk.

Clinical Interpretation Summary • If current LDL-C is higher than the reference, the predicted risk increases multiplicatively; if lower, it decreases. • The absolute risk difference is often more actionable for therapy decisions than the relative increment alone. • Always interpret in the context of the patient’s overall risk profile, preferences, therapy tolerability, and guideline recommendations.